Previous Close | 1.2500 |
Open | 1.2500 |
Bid | 0.0000 |
Ask | 2.1000 |
Strike | 60.00 |
Expire Date | 2024-05-17 |
Day's Range | 1.2500 - 1.2500 |
Contract Range | N/A |
Volume | |
Open Interest | 1 |
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology Association (EHA) Annual Meeting KT-333 Phase 1 study ongoing with additional data expected in the second half of 2024 WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using
WATERTOWN, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: BofA Securities 2024 Health Care Conference in Las Vegas, NV on May 15 at 4:20 p.m. PT; andTD Cowen 5th Annual Oncology Innovation Virtual Summit on May 28 at 1:
It's been a pretty great week for Kymera Therapeutics, Inc. ( NASDAQ:KYMR ) shareholders, with its shares surging 12...